ModuLife vs Aidy for Crohn's: Diet Program or Daily Tracker?
By the Aidy Editorial Team
First Published May 21, 2026Last Updated Aug 19, 2026
ModuLife's site describes a clinician-guided Crohn's Disease Exclusion Diet app, while Aidy supports free daily Crohn's care tracking.
Quick answer: Choose Aidy as the primary Crohn's tracker for free, direct access to symptoms, stool, meals, medication, biologic schedules, modified HBI trends, and appointment reports. ModuLife's claimed exception applies when a trained clinician prescribes CDED with partial enteral nutrition and provides program access.
| Decision factor | Aidy | ModuLife (public claims) |
|---|---|---|
| Best for | Crohn's management | Guided CDED plus PEN |
| Daily IBD record | Symptoms, stool, meals | Diet adherence and wellbeing |
| Treatment tools | Medicines and biologics | Diet phases and specialist messaging |
| Reports and insights | Modified HBI and reports | Diet progress for professionals |
| Access and cost | Free; iPhone and text | Provider invitation; costs vary |
| Overall pick | Primary Crohn's tracker | Prescribed CDED delivery |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
ModuLife Requires a Participating Provider
The US ModuLife App Store listing is free to download, but its first access note says the platform is available only through participating trained healthcare providers. The website likewise says ModuLife should be used under medical supervision and that a trained professional sets up access. The company claims its public provider finder can help locate participating practices, although availability may vary by geography.
The public ModuLife cost is unclear because storefront and US pages give no single price for professional support, formula, or other care. Someone considering the program should ask the provider what the invitation includes, whether visits or nutrition products carry separate costs, how long access lasts, and what records remain available afterward. Aidy is free with no paid patient subscription. Its full Crohn's tracking workflow needs no purchase or provider invitation for routine use.
A Focused Diet Platform Has Genuine Strengths
A fair ModuLife app review should credit how it turns a demanding diet protocol into a guided workflow. Its store listing advertises phase-specific meal plans, hundreds of CDED-friendly recipes, educational videos, food-intake and adherence logs, wellbeing tracking, and private messaging with nutrition specialists. It also claims Apple Health step tracking. The Android listing claims the same core program and shows a July 2025 update.
That narrow focus is valuable when CDED is actually the treatment plan. ModuLife claims to tell a member what fits the current phase and keep a nutrition professional within reach. Aidy does not reproduce a prescribed CDED menu, partial-enteral-nutrition calculation, or program-specific recipe library. As a Crohn's food tracker, Aidy accepts meal photos or descriptions and looks for personal food-symptom associations. ModuLife is better for adherence to one defined diet; Aidy is better for retaining food observations alongside the rest of Crohn’s care.
Evidence Supports CDED More Than the App Itself
CDED has meaningful evidence in selected populations. A 2019 pediatric randomized trial associated CDED plus PEN with better tolerance than exclusive enteral nutrition and more sustained corticosteroid-free remission at week 12. An adult pilot trial reported promising clinical and endoscopic results while calling for a larger trial. A later pediatric trial was underpowered and did not show superiority at week 14.
The AGA diet update says CDED may help some people with relatively recent mild-to-moderate Crohn's and recommends registered-dietitian involvement. That evidence supports a clinician-guided diet, not an independent effect from the software. A 2025 cohort study reported generally positive experiences with CDED and ModuLife, but could not isolate the app's effect.
Aidy Covers More of Crohn’s Treatment
Aidy’s feature set is wider. It includes Bristol stool entries, symptom severity, custom symptoms, meal capture, routine medication adherence, and a unified daily feed. Biologic tools include induction and maintenance schedules, dose countdowns, injection-site rotation, injection or infusion check-ins, and later interval or route changes. It also creates doctor-ready reports and follows a modified Harvey-Bradshaw Index from self-reported data.
ModuLife’s public descriptions emphasize diet adherence and wellbeing. They do not describe detailed stool fields, medication reminders, biologic phases, HBI trends, or a complete appointment report. That gap is decisive for someone wanting one record across changing treatments. Neither app can confirm mucosal inflammation. The AGA Crohn’s biomarker guideline recommends combining symptoms with biomarkers for many monitoring decisions, and NIDDK treatment guidance describes medicines, bowel rest, and surgery among clinician-selected approaches. Aidy organizes the information around that care without presenting a diet as universally appropriate.
Privacy, Devices, and the Better Overall Fit
Apple and Google list ModuLife for iPhone, iPad, and Android. Apple says it may link several data categories to identity. Its privacy notice, dated February 2019, describes health-history, device, activity, provider, and usage data, so a current check is worthwhile. Aidy data is encrypted, exportable, and deletable, with no ads or sale of patient information.
ModuLife fits people whose trained clinician has recommended CDED plus PEN and whose safe adherence benefits from recipes, phased plans, and nutrition messaging. Aidy is the stronger ModuLife alternative for everyday symptoms, stools, medication, biologics, HBI trends, and appointments. ModuLife guides one evidence-informed nutrition protocol. Aidy preserves a free record across Crohn’s care.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.